|Bid||1.2500 x 1300|
|Ask||1.7600 x 1100|
|Day's Range||1.3500 - 1.4100|
|52 Week Range||1.0900 - 2.9100|
|Beta (3Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA. The Platform Presentation titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation is being delivered by David Stamler, MD, Chief Medical Officer & Senior VP Clinical Development.
Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5th May featuring data from the company’s Phase 1 clinical trial and a Poster Presentation featuring pre-clinical data on Thursday 9th May.